In this episode of Think Small, Alex sits down with David Esposito, CEO of ONL Therapeutics, for a rare, behind-the-scenes look at the long, high-stakes journey of bringing a new drug to market. From university-born science and early discovery work to the realities of fundraising, clinical trials, and navigating investor expectations,

David breaks down how ONL is advancing a promising therapy to protect retinal cells and slow vision loss in age-related macular degeneration. It’s a candid, fast-moving conversation about innovation, risk, and the grit required to push life-changing treatments toward FDA approval.

Connect:

LinkedIn: https://www.linkedin.com/in/davidesposito2/

Website:  ...